October 06, 2025
Gilead Sciences Inc. said Monday it is keeping generic forms of its HIV treatment Biktarvy off of the market until 2036 following a series of settlements with competitors.
September 02, 2025
A Gilead Sciences Inc. competitor has agreed not to sell a generic version of Gilead's human immunodeficiency virus treatment Biktarvy until a trio of patents expire, according to a proposal by the parties to end infringement allegations.
May 10, 2022
Gilead Sciences Inc. has initiated a drug patent suit against a trio of competitors in Delaware federal court, seeking to block three generic versions of its human immunodeficiency virus treatment Biktarvy.